Clinical standards for the diagnosis and management of asthma in low- and middle-income countries
BACKGROUND: The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs).METHODS: A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards.RESULTS: Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.g., salbutamol with or without ipratropium bromide) and a single dose of intravenous magnesium sulphate should be considered; Standard 8, All individuals with asthma should receive education about asthma and a personalised action plan; Standard 9, Inhaled medications (excluding dry-powder devices) should be administered via an appropriate spacer device in both adults and children. Children aged 0-3 years will require the spacer to be coupled to a face mask; Standard 10, Children aged <5 years with asthma should receive a SABA as-needed at step 1 and an inhaled corticosteroid (ICS) to cover periods of wheezing due to respiratory viral infections, and SABA as-needed and daily ICS from step 2 upwards; Standard 11, Children aged 6-11 years with asthma should receive an ICS taken whenever an inhaled SABA is used; Standard 12, All adolescents aged 12-18 years and adults with asthma should receive a combination inhaler (ICS and rapid onset of action long-acting beta-agonist [LABA] such as budesonide-formoterol), where available, to be used either as-needed (for mild asthma) or as both maintenance and reliever therapy, for moderate to severe asthma; Standard 13, Inhaled SABA alone for the management of patients aged >12 years is not recommended as it is associated with increased risk of morbidity and mortality. It should only be used where there is no access to ICS.The following standards (14-18) are for settings where there is no access to inhaled medicines. Standard 14, Patients without access to corticosteroids should be provided with a single short course of emergency oral prednisolone; Standard 15, Oral SABA for symptomatic relief should be used only if no inhaled SABA is available. Adjust to the individual's lowest beneficial dose to minimise adverse effects; Standard 16, Oral leukotriene receptor antagonists (LTRA) can be used as a preventive medication and is preferable to the use of long-term oral systemic corticosteroids; Standard 17, In exceptional circumstances, when there is a high risk of mortality from exacerbations, low-dose oral prednisolone daily or on alternate days may be considered on a case-by-case basis; Standard 18. Oral theophylline should be restricted for use in situations where it is the only bronchodilator treatment option available.CONCLUSION: These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease - 27(2023), 9 vom: 01. Sept., Seite 658-667 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jayasooriya, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9PHQ9Y1OLM |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 14.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5588/ijtld.23.0203 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361069375 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361069375 | ||
| 003 | DE-627 | ||
| 005 | 20231227131507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5588/ijtld.23.0203 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM361069375 | ||
| 035 | |a (NLM)37608484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jayasooriya, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical standards for the diagnosis and management of asthma in low- and middle-income countries |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs).METHODS: A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards.RESULTS: Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.g., salbutamol with or without ipratropium bromide) and a single dose of intravenous magnesium sulphate should be considered; Standard 8, All individuals with asthma should receive education about asthma and a personalised action plan; Standard 9, Inhaled medications (excluding dry-powder devices) should be administered via an appropriate spacer device in both adults and children. Children aged 0-3 years will require the spacer to be coupled to a face mask; Standard 10, Children aged <5 years with asthma should receive a SABA as-needed at step 1 and an inhaled corticosteroid (ICS) to cover periods of wheezing due to respiratory viral infections, and SABA as-needed and daily ICS from step 2 upwards; Standard 11, Children aged 6-11 years with asthma should receive an ICS taken whenever an inhaled SABA is used; Standard 12, All adolescents aged 12-18 years and adults with asthma should receive a combination inhaler (ICS and rapid onset of action long-acting beta-agonist [LABA] such as budesonide-formoterol), where available, to be used either as-needed (for mild asthma) or as both maintenance and reliever therapy, for moderate to severe asthma; Standard 13, Inhaled SABA alone for the management of patients aged >12 years is not recommended as it is associated with increased risk of morbidity and mortality. It should only be used where there is no access to ICS.The following standards (14-18) are for settings where there is no access to inhaled medicines. Standard 14, Patients without access to corticosteroids should be provided with a single short course of emergency oral prednisolone; Standard 15, Oral SABA for symptomatic relief should be used only if no inhaled SABA is available. Adjust to the individual's lowest beneficial dose to minimise adverse effects; Standard 16, Oral leukotriene receptor antagonists (LTRA) can be used as a preventive medication and is preferable to the use of long-term oral systemic corticosteroids; Standard 17, In exceptional circumstances, when there is a high risk of mortality from exacerbations, low-dose oral prednisolone daily or on alternate days may be considered on a case-by-case basis; Standard 18. Oral theophylline should be restricted for use in situations where it is the only bronchodilator treatment option available.CONCLUSION: These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Albuterol |2 NLM | |
| 650 | 7 | |a QF8SVZ843E |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 700 | 1 | |a Stolbrink, M |e verfasserin |4 aut | |
| 700 | 1 | |a Khoo, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Sunte, I T |e verfasserin |4 aut | |
| 700 | 1 | |a Awuru, J I |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, D C |e verfasserin |4 aut | |
| 700 | 1 | |a Spanevello, A |e verfasserin |4 aut | |
| 700 | 1 | |a Visca, D |e verfasserin |4 aut | |
| 700 | 1 | |a Centis, R |e verfasserin |4 aut | |
| 700 | 1 | |a Migliori, G B |e verfasserin |4 aut | |
| 700 | 1 | |a Ayuk, A C |e verfasserin |4 aut | |
| 700 | 1 | |a Buendia, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Awokola, B I |e verfasserin |4 aut | |
| 700 | 1 | |a Del-Rio-Navarro, B E |e verfasserin |4 aut | |
| 700 | 1 | |a Muteti-Fana, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lao-Araya, M |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarella, P |e verfasserin |4 aut | |
| 700 | 1 | |a Badellino, H |e verfasserin |4 aut | |
| 700 | 1 | |a Somwe, S W |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, M P |e verfasserin |4 aut | |
| 700 | 1 | |a Garcí-Corzo, J R |e verfasserin |4 aut | |
| 700 | 1 | |a Bekele, A |e verfasserin |4 aut | |
| 700 | 1 | |a Soto-Martinez, M E |e verfasserin |4 aut | |
| 700 | 1 | |a Ngahane, B H M |e verfasserin |4 aut | |
| 700 | 1 | |a Florin, M |e verfasserin |4 aut | |
| 700 | 1 | |a Voyi, K |e verfasserin |4 aut | |
| 700 | 1 | |a Tabbah, K |e verfasserin |4 aut | |
| 700 | 1 | |a Bakki, B |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, A |e verfasserin |4 aut | |
| 700 | 1 | |a Garba, B L |e verfasserin |4 aut | |
| 700 | 1 | |a Salvador, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, G B |e verfasserin |4 aut | |
| 700 | 1 | |a Falade, A G |e verfasserin |4 aut | |
| 700 | 1 | |a ŽivkoviĆ, Zorica |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Tapia, S J |e verfasserin |4 aut | |
| 700 | 1 | |a Erhabor, G E |e verfasserin |4 aut | |
| 700 | 1 | |a Zar, H |e verfasserin |4 aut | |
| 700 | 1 | |a Gemicioglu, B |e verfasserin |4 aut | |
| 700 | 1 | |a Brandão, H V |e verfasserin |4 aut | |
| 700 | 1 | |a Kurhasani, X |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sharif, N |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, V |e verfasserin |4 aut | |
| 700 | 1 | |a Ranasinghe, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Kudagammana, S T |e verfasserin |4 aut | |
| 700 | 1 | |a Masjedi, M R |e verfasserin |4 aut | |
| 700 | 1 | |a Velásquez, J N |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cherrez-Ojeda, I |e verfasserin |4 aut | |
| 700 | 1 | |a Valdeavellano, L F M |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, R M |e verfasserin |4 aut | |
| 700 | 1 | |a Mesonjesi, E |e verfasserin |4 aut | |
| 700 | 1 | |a Morfin-Maciel, B M |e verfasserin |4 aut | |
| 700 | 1 | |a Ndikum, A E |e verfasserin |4 aut | |
| 700 | 1 | |a Mukiibi, G B |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, B K |e verfasserin |4 aut | |
| 700 | 1 | |a Yusuf, O |e verfasserin |4 aut | |
| 700 | 1 | |a Taright-Mahi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Mérida-Palacio, J V |e verfasserin |4 aut | |
| 700 | 1 | |a Kabra, S K |e verfasserin |4 aut | |
| 700 | 1 | |a Nkhama, E |e verfasserin |4 aut | |
| 700 | 1 | |a Filho, N R |e verfasserin |4 aut | |
| 700 | 1 | |a Zhjegi, V B |e verfasserin |4 aut | |
| 700 | 1 | |a Mortimer, K |e verfasserin |4 aut | |
| 700 | 1 | |a Rylance, S |e verfasserin |4 aut | |
| 700 | 1 | |a Masekela, R R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease |d 1998 |g 27(2023), 9 vom: 01. Sept., Seite 658-667 |w (DE-627)NLM093757409 |x 1815-7920 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:658-667 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5588/ijtld.23.0203 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 9 |b 01 |c 09 |h 658-667 | ||